Ampio Pharmaceuticals, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) securities between December 14, 2017 and August 7, 2018.
According to the Ampio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.
“Ampio Pharmaceuticals, Inc.”
If you suffered a loss in Ampio you have until October 24, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.